United Therapeutics Corporation (UTHR)
| Market Cap | 24.58B +86.9% |
| Revenue (ttm) | 3.17B +5.9% |
| Net Income | 1.29B +6.3% |
| EPS | 27.07 +7.8% |
| Shares Out | 42.45M |
| PE Ratio | 21.45 |
| Forward PE | 20.14 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 190,918 |
| Open | 599.00 |
| Previous Close | 596.76 |
| Day's Range | 580.45 - 599.00 |
| 52-Week Range | 272.12 - 609.35 |
| Beta | 0.60 |
| Analysts | Buy |
| Price Target | 579.21 (+0.04%) |
| Earnings Date | May 6, 2026 |
About UTHR
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of tre... [Read more]
Financial Performance
In 2025, United Therapeutics's revenue was $3.18 billion, an increase of 10.61% compared to the previous year's $2.88 billion. Earnings were $1.33 billion, an increase of 11.68%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for UTHR stock is "Buy." The 12-month stock price target is $579.21, which is an increase of 0.04% from the latest price.
News
United Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
Wells Fargo upgraded United Therapeutics (UTHR) to Overweight from Equal Weight with a $738 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial...
United Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
Wells Fargo upgraded United Therapeutics (UTHR) to Overweight from Equal Weight with a price target of $735, up from $575. The firm says Ralinepag DPI brings confidence in United Therapeutics’
United Therapeutics reports Q1 EPS $5.82, consensus $6.86
Reports Q1 revenue $781.5M, consensus $797.38M. “In Q1, we extended our run of clinical success, with positive results from both our ADVANCE OUTCOMES and TETON-1 studies,” said CEO Martine Rothblatt.
United Therapeutics reports Q1 EPS $5.82, consensus $6.86
Reports Q1 revenue $781.5M, consensus $797.38M. “In Q1, we extended our run of clinical success, with positive results from both our ADVANCE OUTCOMES and TETON-1 studies,” said CEO Martine Rothblatt.
United Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 revenue reached $782M, with TYVASO and Ralinepag phase III trials showing best-in-class results. Both drugs are expected to drive revenue beyond $4B by 2027, with multiple new formulations and indications in development.
United Therapeutics Corporation Reports First Quarter 2026 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ...
United Therapeutics announces retirement of Professor Dwek from board
United Therapeutics (UTHR) Corporation announced that the term for Professor Raymond Dwek, C.B.E., F.R.S., as a member of the Board of Directors will expire at the 2026 Annual Meeting of
United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the term for Professor Raymond Dw...
United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2026 financial results in a pre...
United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that 11 new data presentations across ...
United Therapeutics price target raised to $519 from $471 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on United Therapeutics (UTHR) to $519 from $471 and keeps an Equal Weight rating on the shares. The firm adjusted
United Therapeutics initiated with an Outperform at Raymond James
Raymond James last night initiated coverage of United Therapeutics (UTHR) with an Outperform rating and $700 price target The firm believes $5B in peak sales is achievable for Tyvaso in
United Therapeutics initiated with an Outperform at Raymond James
Raymond James initiated coverage of United Therapeutics (UTHR) with an Outperform rating and $700 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking fin...
United Therapeutics announces FDA granted RMAT designation to miroliverELAP
United Therapeutics (UTHR) announced that the U.S. Food and Drug Administration, FDA, has granted Regenerative Medicine Advanced Therapy, RMAT, designation to the company’s investigational miroliverEL...
United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administra...
United Therapeutics price target raised to $700 from $643 at RBC Capital
RBC Capital raised the firm’s price target on United Therapeutics (UTHR) to $700 from $643 and keeps an Outperform rating on the shares as part of the firm’s broader research
United Therapeutics price target raised to $660 from $600 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on United Therapeutics (UTHR) to $660 from $600 and keeps a Buy rating on the shares as the firm argues that the data
United Therapeutics price target raised to $626 from $569 at BofA
BofA analyst Jason Gerberry raised the firm’s price target on United Therapeutics (UTHR) to $626 from $569 and keeps a Neutral rating on the shares. Based on the combined results
United Therapeutics price target raised to $575 from $486 at Wells Fargo
Wells Fargo raised the firm’s price target on United Therapeutics (UTHR) to $575 from $486 and keeps an Equal Weight rating on the shares. The firm says positive data form
United Therapeutics rises 12.6%
United Therapeutics (UTHR) is up 12.6%, or $65.82 to $588.65. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks
RBC sees high probability of approval in IPF after United’s TETON-1 clears bar
RBC Capital analyst Lisa Walter notes Outperform-rated United Therapeutics (UTHR) announced that its Phase III TETON-1 pivotal study of nebulized Tyvaso for idiopathic pulmonary fibrosis met its prima...
Jefferies sees 15%-25% move in United Therapeutics after TETON-1 study hits
Jefferies notes that United Therapeutics (UTHR)’ TETON-1 study evaluating the use of nebulized Tyvaso for the treatment of idiopathic pulmonary fibrosis met its primary efficacy endpoint, “even exceed...
United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-1 study evaluating the ...
United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the New England Journal of Medici...
United Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Recent clinical trial successes position Tyvaso and ralinepag as leading therapies for pulmonary diseases, with rapid commercialization and significant revenue growth expected. The pipeline features innovative inhalers and organ manufacturing advances, while AI-driven models are streamlining drug development.